# Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy

> **NCT03025399** · EARLY_PHASE1 · UNKNOWN · sponsor: **Fengmei Lian** · enrollment: 384 (estimated)

## Conditions studied

- Diabetic Non-proliferative Retinopathy
- Type2 Diabetes

## Interventions

- **DRUG:** Tangwang prescription
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03025399
- **Lead sponsor:** Fengmei Lian
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02
- **Primary completion:** 2019-05
- **Final completion:** 2020-05
- **Target enrollment:** 384 (ESTIMATED)
- **Last updated:** 2017-01-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03025399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03025399, "Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03025399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*